Oliver-Med s.r.o.
- Address
- lock Available on a paid plan
Digestive System Diseases
The outpatient department at Oliver-Med s.r.o. is investigating how the gut microbiota responds to therapeutic interventions during antibiotic therapy for early Lyme borreliosis. The goal is to improve digestive health outcomes for patients receiving antibiotics.
- Probiotic Saccharomyhiptes boulardii impact on gut flora
- Interaction between antibiotics and microbiome in early Lyme disease
- Strategies to preserve digestive function during infection treatment
Research at this Slovakian site supports better management of digestive system disorders through microbiome‑focused studies.
Immune System Diseases
Clinical work in the allergy unit examines the effectiveness of novel allergen extracts for children with allergic rhinoconjunctivitis caused by grass pollen and birch pollen. These studies aim to reduce symptoms and reliance on rescue medication.
- Pediatric grass pollen allergy treatment
- Birch pollen‑induced rhinoconjunctivitis in adolescents
- Long‑term efficacy of allergen immunotherapy
The center’s immune‑focused trials help shape future allergy care for young patients.
Nutritional and Metabolic Diseases
In the metabolic clinic, researchers are evaluating new oral agents that aim to lower blood sugar and promote weight loss in individuals with type 2 diabetes, overweight, or obesity. The studies assess dose‑response relationships and overall impact on glycemic control and body weight.
- Dose‑response of emerging therapy on HbA1c
- Weight reduction outcomes in diabetic patients
- Comparative effectiveness versus placebo
Oliver-Med s.r.o.’s metabolic research contributes to advancing treatment options for diabetes and obesity.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Novo Nordisk A/S1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oliver-Med s.r.o.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Dose-Response Study of NNC0487-0111 in Type 2 Diabetes Patients Inadequately Controlled with Metformin and/or SGLT2 Inhibitors | Novo Nordisk A/S | Phase II | Not Recruiting | Jul 2024 | Oct 2025 |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 12 Grass Pollen Mixture | 1 | Unknown | 2024-09-06 | 2024-09-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.